Xenia M Hart is an expert in Psychiatry at Central Institute of Mental Health (Germany). Xenia M Hart has authored 48 publications, the most recent in 2026. SLR score: 160 (community average: 125). How the SLR is computed.

LeadR Profile

160 ScienceLeadR Reputation 160
Network Map

Psychiatry

Subspecialties: Pharmacy - Neurology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2020 - 2026

Source: PubMed

Central Institute of Mental Health

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 48

Citations

Citations: 193 1st author: 18 Last author: 12 Unique author: 1


Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Therapeutic drug monitoring of sertraline and symptom change in major depressive disorder: a naturalistic outpatient study.
PMID 42484420 — serum, pharmaceutical preparations, drug monitoring, depressive disorder, sertraline, therapeutics, outpatients, depressive disorder, major
Int J Psychiatry Clin Pract20260
Editorial.
PMID 42409051
Pharmacopsychiatry20260
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2026 - Pharmacokinetic, pharmacogenetic and clinical aspects.
PMID 42392224 — pharmaceutical preparations, drug monitoring, drug therapy, psychology, clinical, neurophysiology, therapeutics, plasma
Pharmacopsychiatry20260
Therapeutic Drug Monitoring of Cannabinoids: Therapeutic Reference Ranges for Delta-9-tetrahydrocannabinol in Medical Cannabis, Nabiximols, Dronabinol and Nabilone.
PMID 42269696 — dronabinol, blood, pain, pharmaceutical preparations, drug monitoring, tics, neurophysiology, therapeutics, cannabinoids, medical marijuana
Pharmacopsychiatry20260
High Clozapine Serum Levels Do Not Improve Response: An Observational Study in Patients with Schizophrenia Treated with Clozapine in a Naturalistic Setting.
PMID 42161261 — serum, fluvoxamine, schizophrenia, neurophysiology, psychopharmacology, clozapine, therapeutics, smoking
Pharmacopsychiatry20260

LeadR Networks

Main global connection map